Do analysts recommend CPHI or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CPHI or THAR more profitable?

Tharimmune has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% Tharimmune N/A -588.45% -264.41%

Does the media prefer CPHI or AADI?

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Aadi Bioscience's average media sentiment score of 0.91 beat China Pharma's score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aadi Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RANI or CPHI?

Rani Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 899.89%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rani Therapeutics is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer RANI or CPHI?

In the previous week, Rani Therapeutics had 9 more articles in the media than China Pharma. MarketBeat recorded 10 mentions for Rani Therapeutics and 1 mentions for China Pharma. Rani Therapeutics' average media sentiment score of 1.03 beat China Pharma's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CPHI or ENGN?

enGene has a consensus price target of $12.68, indicating a potential upside of 659.39%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21

Is CPHI or ENGN more profitable?

enGene has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. enGene's return on equity of -55.83% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% enGene N/A -55.83% -45.74%

Does the media favor CPHI or ENGN?

In the previous week, enGene had 9 more articles in the media than China Pharma. MarketBeat recorded 10 mentions for enGene and 1 mentions for China Pharma. enGene's average media sentiment score of 0.30 beat China Pharma's score of 0.00 indicating that enGene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 1 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CYPH or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

China Pharma (CPHI) Competitors

$0.88 +0.02 (+2.48%)

Closing price 06/3/2026 03:59 PM Eastern

Extended Trading

$0.88 +0.00 (+0.45%)

As of 04:00 AM Eastern

Compare

CPHI vs. THAR, AADI, RANI, ENGN, and CYPH

Should you buy China Pharma stock or one of its competitors? MarketBeat compares China Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China Pharma include Tharimmune (THAR), Aadi Bioscience (AADI), Rani Therapeutics (RANI), enGene (ENGN), and Cypherpunk Technologies (CYPH). These companies are all part of the "pharmaceutical products" industry.

How does China Pharma compare to Tharimmune?

China Pharma (NYSE:CPHI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, China Pharma had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for China Pharma and 0 mentions for Tharimmune. China Pharma's average media sentiment score of 0.00 equaled Tharimmune'saverage media sentiment score.

Company	Overall Sentiment
China Pharma	Neutral
Tharimmune	Neutral

China Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

China Pharma has higher revenue and earnings than Tharimmune. China Pharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	8.94	-$3.08M	-$0.55	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Tharimmune has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Tharimmune	N/A	-588.45%	-264.41%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Tharimmune shares are owned by institutional investors. 6.4% of China Pharma shares are owned by company insiders. Comparatively, 6.7% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

China Pharma and Tharimmune tied by winning 6 of the 12 factors compared between the two stocks.

How does China Pharma compare to Aadi Bioscience?

China Pharma (NYSE:CPHI) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, China Pharma and China Pharma both had 1 articles in the media. Aadi Bioscience's average media sentiment score of 0.91 beat China Pharma's score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aadi Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

China Pharma has a net margin of -85.56% compared to Aadi Bioscience's net margin of -246.06%. China Pharma's return on equity of -63.93% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

52.1% of Aadi Bioscience shares are held by institutional investors. 6.4% of China Pharma shares are held by insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

China Pharma has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	8.94	-$3.08M	-$0.55	N/A
Aadi Bioscience	$25.07M	4.12	-$65.76M	-$2.35	N/A

China Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Summary

China Pharma beats Aadi Bioscience on 8 of the 12 factors compared between the two stocks.

How does China Pharma compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

In the previous week, Rani Therapeutics had 9 more articles in the media than China Pharma. MarketBeat recorded 10 mentions for Rani Therapeutics and 1 mentions for China Pharma. Rani Therapeutics' average media sentiment score of 1.03 beat China Pharma's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

China Pharma has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	66.51	-$29.67M	-$0.41	N/A
China Pharma	$3.99M	8.94	-$3.08M	-$0.55	N/A

Rani Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 899.89%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rani Therapeutics is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

30.2% of Rani Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 6.4% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rani Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
China Pharma	-85.56%	-63.93%	-31.42%

Rani Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Summary

Rani Therapeutics beats China Pharma on 10 of the 16 factors compared between the two stocks.

How does China Pharma compare to enGene?

China Pharma (NYSE:CPHI) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

enGene has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. enGene's return on equity of -55.83% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
enGene	N/A	-55.83%	-45.74%

China Pharma has higher revenue and earnings than enGene. China Pharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	8.94	-$3.08M	-$0.55	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

China Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, enGene has a beta of -0.3, indicating that its stock price is 130% less volatile than the broader market.

enGene has a consensus price target of $12.68, indicating a potential upside of 659.39%. Given enGene's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, enGene had 9 more articles in the media than China Pharma. MarketBeat recorded 10 mentions for enGene and 1 mentions for China Pharma. enGene's average media sentiment score of 0.30 beat China Pharma's score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.2% of enGene shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

enGene beats China Pharma on 10 of the 15 factors compared between the two stocks.

How does China Pharma compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cypherpunk Technologies and Cypherpunk Technologies both had 1 articles in the media. Cypherpunk Technologies' average media sentiment score of 1.87 beat China Pharma's score of 0.00 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
China Pharma	Neutral

Cypherpunk Technologies has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Cypherpunk Technologies' return on equity of -48.33% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
China Pharma	-85.56%	-63.93%	-31.42%

30.5% of Cypherpunk Technologies shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cypherpunk Technologies has higher earnings, but lower revenue than China Pharma. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
China Pharma	$3.99M	8.94	-$3.08M	-$0.55	N/A

Cypherpunk Technologies has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Summary

Cypherpunk Technologies beats China Pharma on 7 of the 12 factors compared between the two stocks.

Get China Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPHI vs. The Competition

Export

Metric	China Pharma	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$35.70M	$928.94M	$6.47B	$23.28B
Dividend Yield	N/A	4.84%	2.69%	4.06%
P/E Ratio	-1.60	1.45	22.17	31.00
Price / Sales	8.94	120.65	525.94	23.82
Price / Cash	N/A	20.06	41.34	24.93
Price / Book	1.26	8.15	9.88	4.67
Net Income	-$3.08M	-$3.91M	$3.57B	$1.07B
7 Day Performance	15.62%	-2.01%	-2.45%	-1.10%
1 Month Performance	N/A	N/A	N/A	0.25%
1 Year Performance	-46.70%	110.55%	26.51%	25.20%

China Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPHI China Pharma	N/A	$0.88 +2.5%	N/A	-46.0%	$35.70M	$3.99M	N/A	250	Gap Down
THAR Tharimmune	N/A	$3.23 -1.8%	N/A	+51.4%	$121.87M	N/A	N/A	2	Gap Up
AADI Aadi Bioscience	N/A	$4.78 +0.2%	N/A	+140.2%	$118.05M	$25.07M	N/A	40
RANI Rani Therapeutics	3.0264 of 5 stars	$0.95 +0.2%	$8.75 +819.6%	+57.8%	$117.69M	$1.63M	N/A	110	Positive News Analyst Revision
ENGN enGene	4.0938 of 5 stars	$1.78 +3.5%	$12.68 +612.5%	-60.2%	$115.21M	N/A	N/A	31	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CPHI) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China Pharma (CPHI) Competitors

CPHI vs. THAR, AADI, RANI, ENGN, and CYPH

How does China Pharma compare to Tharimmune?

Summary

How does China Pharma compare to Aadi Bioscience?

Summary

How does China Pharma compare to Rani Therapeutics?

Summary

How does China Pharma compare to enGene?

Summary

How does China Pharma compare to Cypherpunk Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China Pharma (CPHI) Competitors

CPHI vs. THAR, AADI, RANI, ENGN, and CYPH

How does China Pharma compare to Tharimmune?

Does the media prefer CPHI or THAR?

Which has more volatility & risk, CPHI or THAR?

Which has better valuation & earnings, CPHI or THAR?

Is CPHI or THAR more profitable?

Do analysts recommend CPHI or THAR?

Do insiders & institutionals have more ownership in CPHI or THAR?

Summary

How does China Pharma compare to Aadi Bioscience?

Does the media prefer CPHI or AADI?

Is CPHI or AADI more profitable?

Do insiders and institutionals believe in CPHI or AADI?

Which has preferable earnings & valuation, CPHI or AADI?

Which has more risk & volatility, CPHI or AADI?

Summary

How does China Pharma compare to Rani Therapeutics?

Does the media prefer RANI or CPHI?

Which has stronger valuation & earnings, RANI or CPHI?

Do analysts prefer RANI or CPHI?

Do institutionals & insiders believe in RANI or CPHI?

Is RANI or CPHI more profitable?

Which has more risk and volatility, RANI or CPHI?

Summary

How does China Pharma compare to enGene?

Is CPHI or ENGN more profitable?

Which has higher valuation and earnings, CPHI or ENGN?

Which has more risk and volatility, CPHI or ENGN?

Do analysts recommend CPHI or ENGN?

Does the media favor CPHI or ENGN?

Do institutionals and insiders hold more shares of CPHI or ENGN?

Summary

How does China Pharma compare to Cypherpunk Technologies?

Do analysts rate CYPH or CPHI?

Does the media refer more to CYPH or CPHI?

Is CYPH or CPHI more profitable?

Do institutionals and insiders believe in CYPH or CPHI?

Which has preferable valuation & earnings, CYPH or CPHI?

Which has more volatility and risk, CYPH or CPHI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI vs. The Competition

China Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools